Journal articleHuman

Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

Expert opinion on biological therapy, 2012 Jan. Goldstein AL, Hannappel E, Sosne G and 1 others.

Study type

Journal article

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Expert opinion on biological therapy

Published

2012 Jan

PubMed

PMID 22074294 ↗

DOI

10.1517/14712598.2012.634793 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Thymosin β-4 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AnimalsApoptosisBlood PlateletsCell MovementClinical Trials as TopicFibrosisHumansInflammationModels, BiologicalMolecular WeightMyofibroblastsPeptides

Other papers on Thymosin β-4

Randomized controlled trial · 2022

0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

Journal article · 2004

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

Journal article · 2002

Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page